Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4139)
All Articles published online
|
Publishing Process of This Article
|
Apr 24, 2021 (publication date) through Apr 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report. World J Clin Oncol 2021; 12(4): 272-281 [PMID: 33959480 DOI: 10.5306/wjco.v12.i4.272] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm |
| Number | Citing Articles |
| 1 |
Young Kee Shong. Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer. International Journal of Thyroidology 2021; 14(2): 98 doi: 10.11106/ijt.2021.14.2.98
|
| 2 |
Tomohiro Enokida, Makoto Tahara. Management of VEGFR-Targeted TKI for Thyroid Cancer. Cancers 2021; 13(21): 5536 doi: 10.3390/cancers13215536
|